From the editorial desk

Evidence Analysis

Off-label prescribing in longevity medicine: what physicians should know

Nearly every drug tracked on Geroevidence is used off-label for longevity purposes. Here is what that actually means legally and clinically, and what it doesn't.

July 26, 2026  ·  9 min read

Evidence Analysis

How the FDA evaluates anti-aging drug claims (and why "aging" isn't an indication)

No drug is or can currently be FDA-approved for longevity. Here is the specific regulatory reason why, and what the TAME trial's design was built around getting past it.

July 26, 2026  ·  8 min read

Evidence Analysis

Dasatinib monotherapy vs. D+Q: what the senolytics evidence actually covers

Dasatinib is frequently discussed as a standalone senolytic, but every published human senolytic trial has tested it in combination with quercetin. Here is why that distinction matters for the evidence.

July 26, 2026  ·  7 min read

Longevity Science

Caloric restriction and longevity: the biology behind the oldest intervention

Caloric restriction extends lifespan across more species than any other known intervention. Here is the pathway biology connecting it to mTOR, AMPK, and most of the drugs Geroevidence tracks.

July 26, 2026  ·  8 min read

Longevity Science

The klotho protein and aging: what it does and why it's a drug target

Klotho's discovery via a single-gene mouse mutation produced one of the most striking aging phenotypes in mammalian biology. Here is the mechanism behind why it's become a longevity drug target.

July 26, 2026  ·  8 min read

Longevity Science

Quercetin as a senolytic: the evidence behind half of D+Q

Quercetin is half of the D+Q senolytic combination and a widely sold standalone supplement. Its own dedicated senolytic evidence, separate from the combination, is thinner than its ubiquity suggests.

July 26, 2026  ·  7 min read

Longevity Science

NAD+ IV therapy safety: what human data actually exists

NAD+ IV drips are a fast-growing wellness-clinic offering with almost no published efficacy data — and a safety literature that is thinner than the treatment's popularity would suggest.

July 26, 2026  ·  6 min read

Clinical Trials

GlyNAC dosing in published trials: what researchers have actually studied

A summary of the glycine and N-acetylcysteine dosing regimens used in published GlyNAC longevity trials. This describes what researchers have studied — it is not a dosing recommendation.

July 25, 2026  ·  7 min read

Longevity Science

What is a geroprotector? Definition, examples, and current evidence

"Geroprotector" is a scientific term, not a regulatory or marketing one — and that gap is exactly where a lot of longevity-supplement confusion comes from.

July 25, 2026  ·  8 min read

Clinical Trials

The ACCORD trial: what it taught longevity medicine about intensive glucose control

The ACCORD trial found that intensive glucose lowering increased all-cause mortality in high-risk type 2 diabetes patients. It is one of the most important cautionary data points in metabolic longevity medicine.

July 19, 2026  ·  11 min read

Intervention Profiles

Urolithin A and longevity: mitophagy, muscle, and the human evidence

Urolithin A activates mitophagy — the selective clearance of damaged mitochondria. Here is what the published human trial data shows, and what it does not yet show.

July 19, 2026  ·  11 min read

Intervention Profiles

Alpha-ketoglutarate for longevity: the TruAge trial and what the human evidence shows

A TCA cycle intermediate that serves as a cofactor for epigenetic enzymes. The TruAge trial reported biological age reduction — here is what that claim means and how strong the evidence actually is.

July 19, 2026  ·  11 min read

Intervention Profiles

GlyNAC for longevity: glycine, NAC, glutathione, and the human trial evidence

GlyNAC — glycine plus N-acetylcysteine — raises glutathione and targets multiple aging hallmarks. The human RCT evidence is small but notable.

July 19, 2026  ·  10 min read

Intervention Profiles

Resveratrol for longevity: an honest assessment of the evidence in 2026

Resveratrol was the most hyped longevity compound of the 2000s. Here is what the clinical trial evidence actually shows — and why the story is more complicated than either side admits.

July 19, 2026  ·  12 min read

Intervention Profiles

Pterostilbene vs. resveratrol: comparing the longevity evidence

Pterostilbene is a dimethylated resveratrol analog with significantly higher bioavailability. Here is how the two compounds compare on mechanism, pharmacokinetics, and human evidence.

July 19, 2026  ·  10 min read